SUTRO BIOPHARMA, INC.
STROOther · Non-accelerated filer<br>Smaller reporting company · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M | $7.2M |
| Operating income | −$158.4M | −$238.5M | −$89.3M | −$128.9M | −$98.5M | −$71.1M |
| Net income | −$191.1M | −$227.5M | −$106.8M | −$119.2M | −$105.5M | −$19.6M |
| Total assets | $173.8M | $387.2M | $470.7M | $406.9M | $341.4M | $394.1M |
| Total liabilities | $306.3M | $342.6M | $321.1M | $189.9M | $88.8M | $62.1M |
| Equity | −$132.5M | $44.6M | $149.6M | $217.0M | $252.6M | $332.0M |
| EPS (diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.84 |
| Shares out. | 83.8M | 62.4M | 60.2M | 46.4M | 45.9M | 23.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −154.5%
- Net margin
- −186.5%
- Return on equity
- 144.3%
- Return on assets
- −109.9%
- Return on capital (ROCE)
- −160.5%
- Liabilities / assets
- 176.2%
- Debt / equity
- —
- Book value / share
- $-1.58
- Revenue growth (YoY)
- 65.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -22.06distress
- Accruals / assets
- −8.0%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Kynam Capital Management, LpPassive (13G)May 15, 2026
- Samsara Biocapital, L.P.Passive (13G)May 15, 2026
- Affinity Asset Advisors, LlcPassive (13G)May 14, 2026
- Point72 Asset Management, L.P.Passive (13G)May 1, 2026
- Perceptive Advisors LlcPassive (13G)Apr 21, 2026
- Millennium Management LlcPassive (13G)Apr 21, 2026
- Biotechnology Value Fund L PPassive (13G)Feb 18, 2026
- Suvretta Capital Management, LlcPassive (13G)Feb 13, 2026
- Ra Capital Management, L.P.Passive (13G)Aug 14, 2025
- Vanguard Group IncPassive (13G)Jul 29, 2025
- Blackrock, Inc.Passive (13G)Jul 16, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Pauling DavidOfficer — Chief Admin. Ofcr. & GC | Mar 4, 2026 | Option exercise | 675 | $0.00 |
| Chung JaneOfficer — Chief Executive Officer | Mar 4, 2026 | Option exercise | 788 | $0.00 |
| Pauling DavidOfficer — Chief Admin. Ofcr. & GC | Mar 1, 2026 | Option exercise | 500 | $0.00 |
| Gerber Hans-PeterOfficer — CHIEF SCIENTIFIC OFFICER | Mar 1, 2026 | Option exercise | 1,125 | $0.00 |
| Chung JaneOfficer — Chief Executive Officer | Mar 1, 2026 | Option exercise | 688 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 1.2M | 5.6 | +22.1% |
| Apr 30, 2026 | 977,108 | 3.9 | +30.5% |
| Apr 15, 2026 | 748,699 | 2.9 | +17.0% |
| Mar 31, 2026 | 639,714 | 2.8 | +20.1% |
| Mar 13, 2026 | 532,614 | 3.2 | +2.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 14, 2026
- Terminated a material agreement · Results of operationsMar 23, 2026
- Entered a material agreement · Regulation FD disclosureFeb 10, 2026
- Other material eventDec 17, 2025
- Modified shareholder rights · Amended charter or bylaws · Other material eventDec 3, 2025
- Results of operationsNov 6, 2025
- Costs from exit or disposalSep 29, 2025
- Results of operationsAug 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13GMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QMay 14, 2026
- 8-KMay 14, 2026
- SCHEDULE 13G/AMay 14, 2026
- SCHEDULE 13GMay 1, 2026
- ARSApr 22, 2026
- DEFA14AApr 22, 2026
- DEF 14AApr 22, 2026
- SCHEDULE 13G/AApr 21, 2026
- SCHEDULE 13GApr 21, 2026
- EFFECTApr 1, 2026
- 424B3Apr 1, 2026
- CORRESPMar 30, 2026
- UPLOADMar 27, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.